Bavarian Biotech Report 2011/2012 (7MB) - Bio M

Contact:Dr. Luc St-OngeFraunhoferstr. 13/4.OGD-82152 MartinsriedPhone: +49 (0) 89 8932811-100Fax: +49 (0) 89 8932811-111E-Mail: info@affectis.comInternet: www.affectis.comAffectis Pharmaceuticals AGBIOTECH THERAPEUTICS & DIAGNOSTICSKeywords: CNS, Drug Development, Inflammation, Small MoleculesAffectis is a pharmaceutical company focusing on novel drugs for the treatmentof neuroinflammatory diseases. The company is developing AFC-5128,a potent orally active brain-penetrant P2X7 antagonist which shows stronganalgesic effects animal models of neuropathic pain and significantly reducesclinical scores and frequency of relapse in models of multiple sclerosis.The company is also developing AFC-5278 for osteoporosis. Affectis andMerck Serono have entered into a partnership to commercialize certain compoundsfor treating neurodegenerative diseases. Affectis' programs thuscarry the promise of bringing to market new classes of drugs that addressand satisfy unmet medical needs.Agennix AGBIOTECH THERAPEUTICS & DIAGNOSTICSContact:Barbara MüllerFraunhoferstr. 20D-82152 MartinsriedPhone: +49 (0) 89 8565-2693Fax: +49 (0) 89 8565-2610E-Mail: ir@agennix.comInternet: www.agennix.comKeywords: Infectious Diseases, Immune Therapy, Peptide/Protein, Dermatology,Oncology, Small Molecules, Drug DevelopmentAgennix AG is a publicly listed biopharmaceutical company that is developingnovel therapies to improve the length and quality of life of seriously illpatients in areas of major unmet medical need. The Company's most advancedprogram is talactoferrin, an oral immunotherapy that has demonstratedactivity in Phase II studies in non-small cell lung cancer and in severe sepsis.Talactoferrin is currently in Phase III clinical trials in non-small cell lungcancer and a Phase II/III trial in severe sepsis. Other clinical developmentprograms include RGB-286638, a multi-targeted kinase inhibitor in Phase Itesting for cancer, and a topical gel form of talactoferrin for diabetic footulcers.Contact:Prof. Dr. Gottfried BremLarezhausen 2-3D-86567 HilgertshausenPhone: +49 (0) 8250 9279040Fax: +49 (0) 8250 9279049E-Mail: labor@agrobiogen.deInternet: www.agrobiogen.deAgrobiogen GmbHBIOTECH AGRO, FOOD, ENVIRONMENTKeywords: Automation, Xenotransplantation, Genomics, Gene Transfer,Transgenic Animals, AgrobiotechnologyAgrobiogen focuses on and is experienced in the application of moleculargenetictechniques in livestock animals (especially moleculargenetic diagnosticsand gene transfer). Many transgenic rabbit lines and several cattleclones have been established. As a service for other biotech companiestransgenic farm animals are generated using conventional microinjectionprocedures and nucleus transfer. Detection of pathogens like BVDV, as wellas parentage control of animals, SNP genotyping and analysis of DNAmarkers are offered as a service for breeders, veterinarians and companies.Agrobiogen has developed a simple labour-saving system for collection oftissue samples and extraction of DNA from millions of animals for highthroughputanalysis.34